The IDIBELL Neurometabolic Diseases team, which is also part of CIBERER, plans to start the study in early 2022 with the anti-inflammatory dimethyl fumarate in patients with this condition.
New clinical trial for adrenoleukodystrophy, a rare disease of brain metabolism Read More »
Under the title, “Re-definition of lung adenocarcinoma transcriptional subtypes using integrative bioinformatic approaches”, David Cordero, Ania Alay, Raúl Marín, Xavier Solé, and Ernest Nadal have collaborated in the work.
According to a study by IDIBELL and the University of Barcelona, when the levels of nutrients and energy decrease, tumor cells are able to detect it and enter a low-energy mode, during which they store all the necessary material to later reactivate their growth.
In adverse conditions, tumor cells create ribosome reservoirs that allow them to survive Read More »
Aptadel comprise the first generation of companies accelerated at the BCN Health Booster, an initiative promoted by the University of Barcelona (UB), Barcelona Science Park (PCB) and the Barcelona City Council, with support from Barcelona Activa and collaboration from Biocat. The project was created under the Barcelona Science Plan and is an example of collaboration
The spin-off Aptadel selected to be part of BCN Health Booster Read More »
Apoptosis is the mechanism by which defective cells in the body promote their own death in order to protect the body. It is a complex process, with many stages, during which the different parts of the cell are degraded. In glioblastoma cells, however, although apoptosis begins, it stops at one of the stages, allowing the
The best known symptom of epilepsy are seizures, more or less recurrent, which may or may not be accompanied by convulsions. In the case of temporal lobe epilepsy, these episodes are caused by an excessive increase in nerve discharges in a certain area of the temporal lobe of the brain. The main form of treatment
New tool to assess epilepsy cases that need surgery Read More »
During the afternoon of last Thursday, November 18 and the morning of Friday, November 19, the second edition of Career Day was held, organized by IDIBELL with the support of the ICO, the University of Barcelona, the Bellvitge University Hospital and the Hospital de Viladecans. This event brought together professionals from the fields of research
IDIBELL is committed to innovation on its 2nd Career Day Read More »
Doctor and researcher Xavier Bosch has been selected this year as the winner of the the International Papillomavirus Society‘s Maurice Hilleman Award. The award, announced on 19 November, acknowledges the professional career and contribution to the development and promotion of the vaccines against this kind of virus. Bosch, principal investigator at the Bellvitge Biomedical Research Institute (IDIBELL), emeritus researcher at the Catalan Institute of
The gene therapy approach designated as orphan drug has reduced the symptoms of MLC in the pre-clinical phase in model mice of the disease.
La Caixa Foundation concedes 35 fellowships for early-stage researchers of any nationality to pursue their PhD studies in the best Spanish and Portuguese research centres and units with excellence distinction: Spanish Seal of Excellence Severo Ochoa, María de Maeztu or Health Institute Carlos III and Portuguese units accredited as “excellent” by the Fundação de Ciência
IDIBELL offers 10 projects for incoming INPhINIT fellowships Read More »
